- |||||||||| Trial completion, Trial primary completion date: Cancer Stem Cells in Multiple Myeloma (clinicaltrials.gov) - Jan 6, 2016
P=N/A, N=96, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Jan 2016
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment change: Interleukin-2 Treatment for Wiskott-Aldrich Syndrome (clinicaltrials.gov) - Dec 31, 2015 P1, N=15, Recruiting, Active, not recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Nov 2015; PI left the institution N=11 --> 15
- |||||||||| Trial primary completion date: Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Dec 29, 2015
P2, N=30, Suspended, N=11 --> 15 Trial primary completion date: Nov 2014 --> Jan 2016
- |||||||||| Enrollment closed, Trial primary completion date: MBD: Standardisation of Investigations of Mild Bleeding Disorders (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=300, Active, not recruiting, Trial primary completion date: Aug 2015 --> Aug 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Apr 2016
- |||||||||| Xyntha (moroctocog alfa) / Pfizer
Trial primary completion date, Adverse events: Study Evaluating Pharmacovigilance Of Refacto AF (clinicaltrials.gov) - Dec 19, 2015 P=N/A, N=140, Recruiting, Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Apr 2016 --> Oct 2017
- |||||||||| bortezomib / Generic mfg.
Trial primary completion date: Autophagy Induction After Bortezomib for Myeloma (clinicaltrials.gov) - Dec 16, 2015 P0, N=15, Recruiting, Not yet recruiting --> Recruiting Trial primary completion date: Apr 2015 --> Apr 2016
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: OSA in EDS: Obstructive Sleep Apnoea in Ehlers-Danlos Syndrome (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=200, Completed, N=40 --> 0 Enrolling by invitation --> Completed | N=100 --> 200 | Trial primary completion date: Jul 2017 --> Dec 2015
- |||||||||| Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Dec 6, 2015 P1, N=60, Active, not recruiting, Trial primary completion date: Nov 2018 --> Jul 2018 Trial primary completion date: Dec 2015 --> Dec 2016
- |||||||||| Kymriah (tisagenlecleucel-T) / Novartis
Enrollment closed: CART-19 for Multiple Myeloma (clinicaltrials.gov) - Dec 4, 2015 P1, N=13, Active, not recruiting, Recruiting --> Completed | N=20 --> 8 Completed --> Active, not recruiting
- |||||||||| Trial primary completion date: Impact of Vasculitis on Employment and Income (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=400, Recruiting, Completed --> Active, not recruiting Trial primary completion date: Sep 2015 --> Jan 2016
- |||||||||| lenalidomide / Generic mfg.
Trial primary completion date: IFM2005-02: Maintenance Therapy Using Lenalidomide in Myeloma (clinicaltrials.gov) - Nov 30, 2015 P3, N=614, Active, not recruiting, Trial primary completion date: Sep 2015 --> Jan 2016 Trial primary completion date: Sep 2015 --> Sep 2016
|